Opko Health Company Profile (NASDAQ:OPK)

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

Opko Health, Inc. (NASDAQ:OPK) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The firm had revenue of $314.20 million for the quarter, compared to the consensus estimate of $322.64 million. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The company's revenue for the quarter was down 12.0% on a year-over-year basis. During the same period last year, the firm posted $0.02 earnings per share. View Opko Health's Earnings History.

Opko Health is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Opko Health.

8 brokerages have issued 12 month target prices for Opko Health's stock. Their predictions range from $6.50 to $25.00. On average, they expect Opko Health's share price to reach $16.43 in the next year. View Analyst Ratings for Opko Health.

Here are some recent quotes from research analysts about Opko Health stock:

• 1. Cantor Fitzgerald analysts commented, "Expect Rayaldee sales to pick up the pace. Sales force expansion for Rayaldee is under way, and OPK has made substantial progress in obtaining formulary access for Rayaldee. With more-extensive insurance coverage, OPK is continuing to expand its field-based sales force to 70 representatives from the original 35. Also, on 6/22/17, OPK announced that the Kidney Disease Improving Global Outcomes (KDIGO) organization had updated its Clinical Practice Guidelines for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)." (8/17/2017)
• 2. According to Zacks Investment Research, "OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. " (8/12/2017)
• 3. Jefferies Group LLC analysts commented, "4Q16 revenues came in well below expectations (-11% vs. consensus). With Rayaldee off to a slow start & no visibility into the timing of reimbursement from Novitas for 4Kscore (two of OPK's only/most important new growth drivers), we see few NT catalysts for the stock & further downside risk to consensus forecasts. Expect shares to open lower on the 4Q rev miss & recalibrated NT expectations for Rayaldee & 4Kscore. PT to $8 (from $10)." (3/2/2017)

Opko Health saw a drop in short interest during the month of July. As of July 31st, there was short interest totalling 72,810,020 shares, a drop of 1.7% from the July 14th total of 74,103,155 shares. Based on an average trading volume of 3,794,361 shares, the days-to-cover ratio is presently 19.2 days. Approximately 21.8% of the shares of the company are sold short.

Some companies that are related to Opko Health include Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Cambrex Corporation (CBM), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Pacira Pharmaceuticals (PCRX), Emergent Biosolutions (EBS), Innoviva (INVA), Impax Laboratories (IPXL) and AKCEA THERAPEUT (AKCA).

Opko Health's management team includes the folowing people:

• Phillip Frost M.D., Chairman of the Board, Chief Executive Officer
• Jane H. Hsiao Ph.D., Vice Chairman of the Board, Chief Technical Officer
• Adam E. Logal, Chief Financial Officer, Senior Vice President
• Steven D. Rubin Esq. J.D., Executive Vice President - Administration, Director
• Akhtar Ashfaq M.D., Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division
• Thomas Nusbickel, Chief Commercial Officer of the Company's Renal Division
• Richard M. Krasno Ph.D., Independent Director
• Richard Alan Lerner M.D., Independent Director
• John A. Paganelli, Independent Director
• Richard C. Pfenniger Jr., Independent Director

Opko Health's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.76%), BlackRock Inc. (4.09%), State Street Corp (2.03%), FMR LLC (0.97%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.57%) and Dimensional Fund Advisors LP (0.32%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard A Lerner and Steven D Rubin. View Institutional Ownership Trends for Opko Health.

Opko Health's stock was sold by a variety of institutional investors in the last quarter, including Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Menora Mivtachim Holdings LTD., Harel Insurance Investments & Financial Services Ltd., FMR LLC, Wells Fargo & Company MN, Scott & Selber Inc., IFP Advisors Inc and Virtu KCG Holdings LLC. View Insider Buying and Selling for Opko Health.

Opko Health's stock was acquired by a variety of institutional investors in the last quarter, including Alps Advisors Inc., State Street Corp, Jaffetilchin Investment Partners LLC, Vanguard Group Inc., Stevens Capital Management LP, BlackRock Inc., Cornerstone Capital Management Holdings LLC. and Schwab Charles Investment Management Inc.. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard A Lerner and Steven D Rubin. View Insider Buying and Selling for Opko Health.

Shares of Opko Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Opko Health stock can currently be purchased for approximately $6.12.